



65-01-66

EXPRESS MAIL NO.: EV 535 903 835 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.: 7,019,030 B2 (U.S. application no. 10/622,618, filed July 17, 2003)

Issued: March 28, 2006

Inventor(s): Muller et al.

For: IMMUNOTHERAPEUTIC AGENTS

Attorney Docket No.: 9516-200-999
(CAM: 501872-999199)

**REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 C.F.R. §1.322**

Attention Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**Certificate
of Correction**
MAY 04 2006

Sir:

Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The correction is listed on the attached Form PTO-1050.

The error was made by the United States Patent and Trademark Office (“USPTO”) in connection with the above patent, wherein at:

claim 18, column 32, line 9, please replace “(B)-” with -- (E)- --.

Enclosed is a copy of a Response to Office Action Under 37 C.F.R. § 1.116 filed in the USPTO in connection with the above-identified patent application on June 27, 2005 (the “Response”) evidencing the corrections in issued claim 18 (*i.e.*, claim 40 in the Response) as set forth above. Further enclosed is a copy (both sides) of a return-receipt postcard evidencing receipt of the Response by the USPTO on June 27, 2005.

No fee is believed to be due in connection with this request since the error was made by the USPTO. Should any fees be required, however, please charge such fees to Jones Day Deposit Account No. 50-3013. Please issue a certificate of correction as soon as possible.

Date: April 27, 2006

Respectfully submitted,
Anthony M. Insogna, Reg. No. 35,203
By: *Michael J. Bruner, Reg. No. 47,458*

By: Michael J. Bruner (Reg. No. 47,458)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, California 92130
(858) 314-1130

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,019,030 B2
DATED : March 28, 2006
INVENTOR(S) : Muller et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At claim 18, column 32, line 9, please replace "(B)-" with -- (E)- --.

MAILING ADDRESS OF SENDER:
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130

PATENT NO.

7,019,030 B2

No. of add'l. copies
@ 30¢ perpage

FORM PTO 1050

MAY 04 2006

ATI: 2221376.1



Express Mail No **EV 452 775 546 US**

Date Mailed: June 27, 2005

Serial No.: **10/622,618**


Filed: July 17, 2003

Inventor: Muller *et al.*

For **NOVEL IMMUNOTHERAPEUTIC AGENTS**

1. Request for Continued Examination (RCE) (in duplicate) with provision to charge the required fee to Jones Day Deposit Account No. 50-3013;
2. Response to Office Action Under 37 C.F.R. § 1.116;
3. Terminal Disclaimer Under 37 C.F.R. § 1.321(c) with provision to charge the required fee to Jones Day Deposit Account No. 50-3013;
4. Revocation and Power of Attorney;
5. Supplemental Information Disclosure Statement; and
6. List of References Cited by Application.

MAIL DATE CANCELLED



File no.: **9516-200-999 (CAM No.: 501872-999199)** Sender: (AMI/MJB)



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES

BUSINESS REPLY MAIL
FIRST-CLASS MAIL PERMIT NO. 1825 NEW YORK NY

POSTAGE WILL BE PAID BY ADDRESSEE

JONES DAY
222 E 41ST ST FL 4
NEW YORK NY 10164-3474



BEST AVAILABLE COPY



Express Mail No.: EV 452 775 546 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Muller <i>et al.</i>	Confirmation No.:	2627
Serial No.:	10/622,618	Art Unit:	1626
Filed:	July 17, 2003	Examiner:	R. Anderson
For:	NOVEL IMMUNOTHERAPEUTIC AGENT	Attorney Docket No: (CAM: 501872-999199)	9516-200-999

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.116

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This responds to the Office Action mailed April 28, 2005 in connection with the above-identified application. Applicants concurrently submit herewith: i) a Terminal Disclaimer Under 37 C.F.R. § 1.321(c) (with provision for the required fee); ii) a Revocation and Power of Attorney; iii) a Supplemental Information Disclosure Statement Under 37 C.F.R. §§ 1.56 and 1.97, including an accompanying List of References Cited by Applicant, listing references A01-A74, B01 to B15 and C01 to C37; and iv) a Request for Continued Examination Under 37 C.F.R. § 1.114 with provision for the required fee (in duplicate).

Amendments to the Claims are reflected on the listing of claims that begins on page 2 of this paper.


Remarks begin on page 6 of this paper.

BEST AVAILABLE COPY

Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in this application.

1. (Previously Presented) A substantially pure (E)-compound, a substantially pure (Z)-compound, or a mixture of (E)- and (Z)-compounds having the formula (I):



wherein:

X is -O-, and R¹ is any alkyl of up to 10 carbon atoms, any monocycloalkyl of up to 10 carbon atoms, any polycycloalkyl of up to 10 carbon atoms, or any benzocyclic alkyl of up to 10 carbon atoms;

R² is nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, or halo; and R³ is (i) phenyl unsubstituted or substituted with 1 or more substituents wherein each substituent is independently a nitro, a cyano, a halo, a trifluoromethyl, a carbethoxy, a carbomethoxy, a carbopropoxy, an acetyl, a carbamoyl, a carbamoyl substituted with an alkyl of 1 to 3 carbon atoms, an acetoxy, a carboxy, a hydroxy, an amino, an amino substituted with an alkyl of 1 to 5 carbon atoms, an alkyl or cycloalkyl of 1 to 10 carbon atoms, or an alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or (ii) phenyl substituted with 1 or more substituents wherein each substituent is independently an alkylidenemethyl of up to 10 carbon atoms, a cycloalkylidenemethyl of up to 10 carbon atoms, a phenyl, or a methylenedioxy.

2. (Canceled).

3. (Currently Amended) The compound of or mixture of claim 1,

wherein:

R² is nitro, cyano, trifluoromethyl, amino, lower alkyl, lower alkoxy, or halo.

4. (Currently amended) The compound of or mixture of claim 1,
wherein:

BEST AVAILABLE COPY

R^1 is alkyl of up to 10 carbon atoms; and


R^2 is trifluoromethyl; lower alkyl, or lower alkoxy.

5. (Previously Presented) The compound of claim 4, wherein:

R^1 is methyl or ethyl; and

R^2 is methoxy or ethoxy.

6. (Original) A substantially pure (E)-compound, a substantially pure (Z)-compound, or a mixture of (E)- and (Z)-compounds having the formula (II):



7. (Previously Presented) The compound or mixture of claim 1 which is:

3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile;

3,3-bis-(3-ethoxy-4-methoxyphenyl)acrylonitrile;

3-(3-propoxy-4-methoxyphenyl)-3-phenylacrylonitrile;

3-(3-ethoxy-4-methoxyphenyl)-3-phenylacrylonitrile;

3,3-bis-(3-cyclopentoxy-4-methoxyphenyl)acrylonitrile;

3-(3-cyclopentoxy-4-methoxyphenyl)-3-phenylacrylonitrile;

3-(3,4-dimethoxyphenyl)-3-phenylacrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(3',5'-dimethoxyphenyl)acrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(3-ethoxy-4-methoxyphenyl)acrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(3'-nitrophenyl)acrylonitrile;

3-(3'-aminophenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(4-nitrophenyl)acrylonitrile;

3-(4-aminophenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile;

3-(4-biphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(4'-fluorophenyl)acrylonitrile;

3-(3,4-dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)acrylonitrile;

3-(3,4-diethylphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile; or

BEST AVAILABLE COPY

3-(3,4-dimethoxyphenyl)-3-(2,5-dichlorophenyl)acrylonitrile.

8-11. (Cancelled).

12. (Original) A pharmaceutical composition comprising a compound or mixture according to claim 1.

13-15. (Cancelled).

16. (Previously Presented) A compound of claim 1, which is an (E)-compound.

17. (Previously Presented) A compound of claim 1, which is an (Z)-compound.

18. (Original) A mixture of claim 1 comprising both (E)- and (Z)-compounds.

19-22. (Cancelled).

23. (Original) A pharmaceutical composition comprising a compound or mixture according to claim 4.

24-26. (Cancelled).

27. (Previously Presented) A compound of claim 4, which is an (E)-compound.

28. (Previously Presented) A compound of claim 4, which is an (Z)-compound.

29. (Original) A mixture of claim 4 comprising both (E)- and (Z)-compounds.

BEST AVAILABLE COPY

30-33. (Cancelled).

34. (Original) A pharmaceutical composition comprising a compound or mixture according to claim 6.

35-37. (Cancelled).

38. (Previously Presented) A compound of claim 6, which is an (E)-compound.

39. (Previously Presented) A compound of claim 6, which is an (Z)-compound.

40. (Original) A mixture of claim 6 comprising both (E)- and (Z)-compounds.

BEST AVAILABLE COPY

Remarks

Claims 1, 3-7, 12, 16-18, 23, 27-29, 34, and 38-40 are pending in this application. Claims 3 and 4 have been amended to correct typographical errors wherein "of" has been replaced with "or." No new matter has been added.

Applicants reserve their rights to pursue any unclaimed subject matter in the present application in one or more divisional, continuation, or continuation-in-part applications.

The Rejection Under Judicially Created Obviousness-Type Double Patenting

On pages 2-12 of the Office Action, various pending claims are rejected under the judicially-created doctrine of obviousness-type double patenting. In particular, certain pending claims are rejected over U.S. Patent No. 5,929,117 ("the '117 patent") under the judicially-created doctrine of obviousness-type double patenting. Applicants submit herewith a Terminal Disclaimer Under 37 C.F.R. § 1.321(c) (with provision for the required fee) disclaiming the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the '117 patent as described in the attached Terminal Disclaimer.

Accordingly, Applicants respectfully submit that the rejection under the judicially-created doctrine of obviousness-type double patenting over the '117 patent has been overcome and must be withdrawn.

Conclusion

Applicants respectfully request that the above amendments and remarks be entered in the present application file. No fee is believed to be due in connection with this Response other than that in connection with the Supplemental Information Disclosure Statement and Terminal Disclaimer; however, in the event that any additional fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: June 27, 2005

Respectfully submitted,
Anthony M. Insogna, Reg. No. 35,203
By: Mark J. Brown, Reg. No. 47,1458
Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130

BEST AVAILABLE COPY